A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: a case report

J Int Med Res. 2020 Oct;48(10):300060520925666. doi: 10.1177/0300060520925666.

Abstract

Introduction: Anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis is an autoimmune-mediated disease that is common in young female patients with ovarian teratomas. With appropriate immunotherapy, most patients achieve a good prognosis. Nevertheless, some patients may be refractory to first- and second-line immunotherapy, thus alternative treatments are required for these patients.Case presentation: We present a case of anti-NMDA receptor encephalitis with ovarian teratoma. After the prompt removal of the teratoma and intense immunotherapy was administered, including an intravenous methylprednisolone pulse, intravenous immunoglobin, plasmapheresis, immunoadsorption, intravenous cyclophosphamide, and rituximab, the patient's neurologic status did not improve. Bilateral salpingo-oophorectomy was then conducted, and intrathecal injection of methotrexate (MTX) and dexamethasone (DXM) was performed. The patient's neurological symptoms improved dramatically, and she achieved a good prognosis after 23 months.

Conclusions: Intrathecal injection of MTX and DXM may be beneficial for treatment of refractory cases of anti-NMDA receptor encephalitis. Additional research is required to elucidate the mechanisms of intrathecal treatment with this therapy.

Keywords: Anti-NMDA receptor encephalitis; auto-immune disease; immunotherapy; intrathecal injection; methotrexate; ovarian teratoma.

Publication types

  • Case Reports

MeSH terms

  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis* / drug therapy
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Injections, Spinal
  • Methotrexate / therapeutic use
  • Salpingo-oophorectomy
  • Teratoma* / drug therapy

Substances

  • Dexamethasone
  • Methotrexate